Efficacy of topical liposomal amphotericin B versus intralesional meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis

Journal of Parasitology Research

Volumn 2011, Issue , 2011, Pages

  Layegh, Pouran ^a   Rajabi, Omid ^b   Jafari, Mahmoud Reza ^b   Emamgholi Tabar Malekshah, Parisa ^c   Moghiman, Toktam ^c   Ashraf, Hami ^b   Salari, Roshanak ^b  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; MEGLUMINE ANTIMONATE;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; FEMALE; HUMAN; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SKIN LEISHMANIASIS; TREATMENT OUTCOME;

EID: 84855569080     PISSN: 20900023     EISSN: 20900031     Source Type: Journal    
DOI: 10.1155/2011/656523     Document Type: Article

References (22)

1. Hepburn N. C., Cutaneous leishmaniasis Clinical and Experimental Dermatology 2000 25 5 363 370
2. Asilian A., Davami M., Comparison between the efficacy of photodynamic therapy and topical paromomycin in the treatment of Old World cutaneous leishmaniasis: a placebo-controlled, randomized clinical trial Clinical and Experimental Dermatology 2006 31 5 634 637 (Pubitemid 44086787)
3. Al-Mohammed H. I., Chance M. L., Bates P. A., Production and characterization of stable amphotericin-resistant amastigotes and promastigotes of Leishmania mexicana Antimicrobial Agents and Chemotherapy 2005 49 8 3274 3280 (Pubitemid 41060571)
4. Croft S. L., Yardley V., Chemotherapy of leishmaniasis Current Pharmaceutical Design 2002 8 4 319 342 (Pubitemid 34460464)
5. Jha T. K., Giri Y. N., Singh T. K., Jha S., Use of amphotericin B in drug-resistant cases of visceral leishmaniasis in North Bihar, India American Journal of Tropical Medicine and Hygiene 1995 52 6 536 538
6. Sundar S., Jha T. K., Thakur C. P., Mishra M., Singh V. P., Buffels R., Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study American Journal of Tropical Medicine and Hygiene 2002 66 2 144 146
7. Thakur C. P., A single high dose treatment of kala-azar with AmBisome (amphotericin B lipid complex): a pilot study International Journal of Antimicrobial Agents 2001 17 1 67 70 (Pubitemid 32008663)
8. Frankenburg S., Glick D., Klaus S., Barenholz Y., Efficacious topical treatment for murine cutaneous leishmaniasis with ethanolic formulations of amphotericin B Antimicrobial Agents and Chemotherapy 1998 42 12 3092 3096 (Pubitemid 28553723)
9. Vardy D., Barenholz Y., Cohen R., Zvulunov A., Biton A., Klaus S., Frankenburg S., Topical amphotericin B for cutaneous leishmaniasis Archives of Dermatology 1999 135 7 856 857
10. Mahmoodi M. R., Mohajery M., Afshari J. T., Shakeri M. T., Panah M. J. Y., Berenji F., Fata A., Molecular identification of Leishmania species causing cutaneous leishmaniasis in Mashhad, Iran Jundishapur Journal of Microbiology 2010 3 4, supplement 9 195 200
11. Shahbazi F., Shahabi S., Kazemi B., Mohebali M., Abadi A. R., Zare Z., Evaluation of PCR assay in diagnosis and identification of cutaneous leishmaniasis: a comparison with the parasitological methods Parasitology Research 2008 103 5 1159 1162
12. Li C., Deng Y., A novel method for the preparation of liposomes: freeze drying of monophase solutions Journal of Pharmaceutical Sciences 2004 93 6 1403 1414 (Pubitemid 38725015)
13. Ellis M., Amphotericin B preparations: a maximum tolerated dose in severe invasive fungal infections? Transplant Infectious Disease 2000 2 2 51 61 (Pubitemid 30262723)
14. AmBisome Summary of Product Characteristics, Gilead Sciences Ltd
15. Hajjaran H., Mohebali M., Razavi M. R., Identification of Leishmania species isolated from human utaneous leishmaniasis, using random amplified polymorphic DNA (RAPD-PCR) Iranian Journal of Public Health 2004 3 4 8 15
16. Hadighi R., Mohebali M., Boucher P., Hajjaran H., Khamesipour A., Ouellette M., Unresponsiveness to glucantime treatment in Iranian cutaneous leishmaniasis due to drug-resistant Leishmania tropica parasites PLoS Medicine 2006 3 5 659 667 (Pubitemid 43807035)
17. Layegh P., Rahsepar S., Rahsepar A. A., Systemic meglumine antimoniate in acute cutaneous leishmaniasis: children versus adults American Journal of Tropical Medicine and Hygiene 2011 84 4 539 542
18. Pardisi A., Capizzi R., Zampetti A., A typical multifocal cutaneous leishmaniasis in an immunocompetent patient treated by liposomal amphotericin B Journal of Infection 2007 54 2 208
19. Amato V. S., Rabello A., Rotondo-Silva A., Kono A., Maldonado T. P. H., Alves I. C., Floeter-Winter L. M., Neto V. A., Shikanai-Yasuda M. A., Successful treatment of cutaneous leishmaniasis with lipid formulations of amphotericin B in two immunocompromised patients Acta Tropica 2004 92 2 127 132 (Pubitemid 39180014)
20. Brown M., Noursadeghi M., Boyle J., Davidson R. N., Successful liposomal amphotericin B treatment of Leishmania braziliensis cutaneous leishmaniasis British Journal of Dermatology 2005 153 1 203 205 (Pubitemid 41044552)
21. Zvulunov A., Cagnano E., Frankenburg S., Barenholz Y., Vardy D., Topical treatment of persistent cutaneous leishmaniasis with ethanolic lipid amphotericin B Pediatric Infectious Disease Journal 2003 22 6 567 569 (Pubitemid 36782201)
22. Vardy D., Barenholz Y., Naftoliev N., Klaus S., Gilead L., Frankenburg S., Efficacious topical treatment for human cutaneous leishmaniasis with ethanolic lipid amphotericin B Transactions of the Royal Society of Tropical Medicine and Hygiene 2001 95 2 184 186 (Pubitemid 34947384)